Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0H2JD
|
||||
| Former ID |
DNCL002324
|
||||
| Drug Name |
Gemcitabine prodrug
|
||||
| Indication | Cancer [ICD9: 140-229; ICD10:C00-C96] | Phase 1 | [1], [2] | ||
| Company |
Eli Lilly
|
||||
| Target and Pathway | |||||
| Target(s) | Ribonucleoside-diphosphatereductase subunit M2 | Target Info | Inhibitor | [3] | |
| Human DNA | Target Info | Inhibitor | [3] | ||
| BioCyc Pathway | Pyrimidine deoxyribonucleotides biosynthesis from CTP | ||||
| Pyrimidine deoxyribonucleotides de novo biosynthesis | |||||
| Guanosine nucleotides de novo biosynthesis | |||||
| Superpathway of pyrimidine deoxyribonucleotides de novo biosynthesis | |||||
| Superpathway of purine nucleotide salvage | |||||
| Purine nucleotides de novo biosynthesis | |||||
| Adenosine deoxyribonucleotides de novo biosynthesis | |||||
| Guanosine deoxyribonucleotides de novo biosynthesis | |||||
| KEGG Pathway | Purine metabolism | ||||
| Pyrimidine metabolism | |||||
| Glutathione metabolism | |||||
| Metabolic pathways | |||||
| p53 signaling pathway | |||||
| NetPath Pathway | EGFR1 Signaling Pathway | ||||
| PANTHER Pathway | p53 pathway | ||||
| De novo purine biosynthesis | |||||
| De novo pyrimidine deoxyribonucleotide biosynthesis | |||||
| Pathway Interaction Database | E2F transcription factor network | ||||
| PathWhiz Pathway | Purine Metabolism | ||||
| Pyrimidine Metabolism | |||||
| Reactome | E2F mediated regulation of DNA replication | ||||
| G1/S-Specific Transcription | |||||
| WikiPathways | Nucleotide Metabolism | ||||
| Retinoblastoma (RB) in Cancer | |||||
| Metabolism of nucleotides | |||||
| Fluoropyrimidine Activity | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01648764) A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread. U.S. National Institutes of Health. | ||||
| REF 2 | Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors. Clin Cancer Res. 2011 Sep 15;17(18):6071-82. | ||||
| REF 3 | Cellular pharmacology of gemcitabine. Ann Oncol. 2006 May;17 Suppl 5:v7-12. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.